Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29563831
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29563831
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Pain+Res
2018 ; 11
(ä): 515-526
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Serotonin receptor agonists in the acute treatment of migraine: a review on their
therapeutic potential
#MMPMID29563831
Negro A
; Koverech A
; Martelletti P
J Pain Res
2018[]; 11
(ä): 515-526
PMID29563831
show ga
Migraine is an important socioeconomic burden and is ranked the sixth cause of
years of life lost because of disability in the general population and the third
cause of years of life lost in people younger than 50 years. The cornerstone of
pharmacological treatment is represented by the acute therapy. The serotonin
(5-hydroxytryptamine [5-HT]) receptor subtype 1(B)/1(D) agonists, called
triptans, are nowadays the first-line acute therapy for patients who experience
moderate-to-severe migraine attacks. Unfortunately, a high percentage of patients
are not satisfied with this acute treatment, either for lack of response or side
effects. Moreover, their mechanism of action based on vasoconstriction makes them
unsuitable for patients with previous cardio- and cerebrovascular diseases and
for those with uncontrolled hypertension. Since the introduction of triptans, no
other acute drug class has passed all developmental stages. The research for a
new drug lacking vasoconstrictive effects led to the development of lasmiditan, a
highly selective 5-HT1(F) receptor agonist with minimized interactions with other
5-HT receptor subtypes. Lasmiditan is considered to be the first member of a new
drug category, the neurally acting anti-migraine agent (NAAMA). Phase II and III
trials had shown superiority compared to placebo and absence of typical
triptan-associated adverse events (AEs). Most of the AEs were related to the
central nervous system, depending on the high permeability through the
blood-brain barrier and mild to moderate severity. The results of ongoing
long-term Phase III trials will determine whether lasmiditan will become
available in the market, and then active triptan comparator studies will assess
patients' preference. Future studies could then explore the safety during
pregnancy and breastfeeding or the risk that overuse of lasmiditan leads to
medication overuse headache.
free
free
free
